Abortion at the Supreme Court (Again)

On March 26, 2024, the Supreme Court will hear argument in a set of cases challenging FDA's approval decisions with respect to mifepristone, a prescription drug product approved for terminating pregnancies and managing miscarriages during early pregnancy. The case has significant implications for reproductive rights, companies that manufacture and sell prescription drugs, and administrative law more generally. Experts from Goodwin's Supreme Court, Commercial Litigation, Life Sciences Regulatory & Compliance, and IP Litigation practices Jaime Santos, Jen Fisher, Susan Lee, and Daryl Wiesen will be at the argument. Join them the day after as they discuss the Justices' questioning, the possible outcomes, and what they might mean for those seeking access to medication abortion, as well as for business regulated by the FDA.

CLE credit will be offered for California, New Jersey, New York, and Pennsylvania.